Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of denosumab (Amgen vs AryoGen Pharmed) on bone mineral density in osteoporotic postmenopausal women
IRCT2017020521315N9Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of denosumab in postmenopausal osteoporosis, sponsored by AryoGen Biopharma. Primary endpoint: Change in bone mineral density. Started Apr 2017; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on IRCT2017020521315N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017020521315N9.